267 related articles for article (PubMed ID: 33146523)
1. Dienone Compounds: Targets and Pharmacological Responses.
Bazzaro M; Linder S
J Med Chem; 2020 Dec; 63(24):15075-15093. PubMed ID: 33146523
[TBL] [Abstract][Full Text] [Related]
2. Sensitivity of Acute Myelocytic Leukemia Cells to the Dienone Compound VLX1570 Is Associated with Inhibition of the Ubiquitin-Proteasome System.
Selvaraju K; Lotfi K; Gubat J; Miquel M; Nilsson A; Hill J; Jensen LD; Linder S; D'Arcy P
Biomolecules; 2021 Sep; 11(9):. PubMed ID: 34572552
[TBL] [Abstract][Full Text] [Related]
3. The proteasome deubiquitinase inhibitor VLX1570 shows selectivity for ubiquitin-specific protease-14 and induces apoptosis of multiple myeloma cells.
Wang X; Mazurkiewicz M; Hillert EK; Olofsson MH; Pierrou S; Hillertz P; Gullbo J; Selvaraju K; Paulus A; Akhtar S; Bossler F; Khan AC; Linder S; D'Arcy P
Sci Rep; 2016 Jun; 6():26979. PubMed ID: 27264969
[TBL] [Abstract][Full Text] [Related]
4. Analysis of determinants for in vitro resistance to the small molecule deubiquitinase inhibitor b-AP15.
Mofers A; Perego P; Selvaraju K; Gatti L; Gullbo J; Linder S; D'Arcy P
PLoS One; 2019; 14(10):e0223807. PubMed ID: 31639138
[TBL] [Abstract][Full Text] [Related]
5. Acute lymphoblastic leukemia cells are sensitive to disturbances in protein homeostasis induced by proteasome deubiquitinase inhibition.
Mazurkiewicz M; Hillert EK; Wang X; Pellegrini P; Olofsson MH; Selvaraju K; D'Arcy P; Linder S
Oncotarget; 2017 Mar; 8(13):21115-21127. PubMed ID: 28423502
[TBL] [Abstract][Full Text] [Related]
6. Re-Evaluating the Mechanism of Action of α,β-Unsaturated Carbonyl DUB Inhibitors b-AP15 and VLX1570: A Paradigmatic Example of Unspecific Protein Cross-linking with Michael Acceptor Motif-Containing Drugs.
Ward JA; Pinto-Fernandez A; Cornelissen L; Bonham S; Díaz-Sáez L; Riant O; Huber KVM; Kessler BM; Feron O; Tate EW
J Med Chem; 2020 Apr; 63(7):3756-3762. PubMed ID: 32109059
[TBL] [Abstract][Full Text] [Related]
7. Structure-function analyses of candidate small molecule RPN13 inhibitors with antitumor properties.
Anchoori RK; Tan M; Tseng SH; Peng S; Soong RS; Algethami A; Foran P; Das S; Wang C; Wang TL; Liang H; Hung CF; Roden RBS
PLoS One; 2020; 15(1):e0227727. PubMed ID: 31940398
[TBL] [Abstract][Full Text] [Related]
8. Synthesis and anti-tumor activity of EF24 analogues as IKKβ inhibitors.
Jin R; Chen Q; Yao S; Bai E; Fu W; Wang L; Wang J; Du X; Wei T; Xu H; Jiang C; Qiu P; Wu J; Li W; Liang G
Eur J Med Chem; 2018 Jan; 144():218-228. PubMed ID: 29351887
[TBL] [Abstract][Full Text] [Related]
9. Small-molecule RA-9 inhibits proteasome-associated DUBs and ovarian cancer in vitro and in vivo via exacerbating unfolded protein responses.
Coughlin K; Anchoori R; Iizuka Y; Meints J; MacNeill L; Vogel RI; Orlowski RZ; Lee MK; Roden RB; Bazzaro M
Clin Cancer Res; 2014 Jun; 20(12):3174-86. PubMed ID: 24727327
[TBL] [Abstract][Full Text] [Related]
10. Targeting the ubiquitin+proteasome system in solid tumors.
Driscoll JJ; Woodle ES
Semin Hematol; 2012 Jul; 49(3):277-83. PubMed ID: 22726552
[TBL] [Abstract][Full Text] [Related]
11. Curcuminoid EF24 enhances the anti-tumour activity of Akt inhibitor MK-2206 through ROS-mediated endoplasmic reticulum stress and mitochondrial dysfunction in gastric cancer.
Chen X; Dai X; Zou P; Chen W; Rajamanickam V; Feng C; Zhuge W; Qiu C; Ye Q; Zhang X; Liang G
Br J Pharmacol; 2017 May; 174(10):1131-1146. PubMed ID: 28255993
[TBL] [Abstract][Full Text] [Related]
12. Design and optimize N-substituted EF24 as effective and low toxicity NF-κB inhibitor for lung cancer therapy via apoptosis-to-pyroptosis switch.
Chen L; Li Q; Zheng Z; Xie J; Lin X; Jiang C; Xu H; Wu X; Wu J; Zhang H
Chem Biol Drug Des; 2019 Jul; 94(1):1368-1377. PubMed ID: 30873716
[TBL] [Abstract][Full Text] [Related]
13. Biological Effects of EF24, a Curcumin Derivative, Alone or Combined with Mitotane in Adrenocortical Tumor Cell Lines.
Bertazza L; Barollo S; Mari ME; Faccio I; Zorzan M; Redaelli M; Rubin B; Armanini D; Mian C; Pezzani R
Molecules; 2019 Jun; 24(12):. PubMed ID: 31212829
[TBL] [Abstract][Full Text] [Related]
14. Design, synthesis, and evaluation of asymmetric EF24 analogues as potential anti-cancer agents for lung cancer.
Wu J; Wu S; Shi L; Zhang S; Ren J; Yao S; Yun D; Huang L; Wang J; Li W; Wu X; Qiu P; Liang G
Eur J Med Chem; 2017 Jan; 125():1321-1331. PubMed ID: 27886548
[TBL] [Abstract][Full Text] [Related]
15. CLEFMA-an anti-proliferative curcuminoid from structure-activity relationship studies on 3,5-bis(benzylidene)-4-piperidones.
Lagisetty P; Vilekar P; Sahoo K; Anant S; Awasthi V
Bioorg Med Chem; 2010 Aug; 18(16):6109-20. PubMed ID: 20638855
[TBL] [Abstract][Full Text] [Related]
16. The 19S Deubiquitinase inhibitor b-AP15 is enriched in cells and elicits rapid commitment to cell death.
Wang X; Stafford W; Mazurkiewicz M; Fryknäs M; Brjnic S; Zhang X; Gullbo J; Larsson R; Arnér ES; D'Arcy P; Linder S
Mol Pharmacol; 2014 Jun; 85(6):932-45. PubMed ID: 24714215
[TBL] [Abstract][Full Text] [Related]
17. Induction of gut proteasome activity in hemorrhagic shock and its recovery by treatment with diphenyldihaloketones CLEFMA and EF24.
Rao G; Houson H; Nkepang G; Yari H; Teng C; Awasthi V
Am J Physiol Gastrointest Liver Physiol; 2018 Aug; 315(2):G318-G327. PubMed ID: 29746173
[TBL] [Abstract][Full Text] [Related]
18. Targeted inhibition of the deubiquitinating enzymes, USP14 and UCHL5, induces proteotoxic stress and apoptosis in Waldenström macroglobulinaemia tumour cells.
Chitta K; Paulus A; Akhtar S; Blake MK; Caulfield TR; Novak AJ; Ansell SM; Advani P; Ailawadhi S; Sher T; Linder S; Chanan-Khan A
Br J Haematol; 2015 May; 169(3):377-90. PubMed ID: 25691154
[TBL] [Abstract][Full Text] [Related]
19. Design, synthesis, and biological evaluation of novel
Xie X; Tu J; You H; Hu B
Drug Des Devel Ther; 2017; 11():1439-1451. PubMed ID: 28553074
[TBL] [Abstract][Full Text] [Related]
20. Targeting the ubiquitin-proteasome pathway to overcome anti-cancer drug resistance.
Narayanan S; Cai CY; Assaraf YG; Guo HQ; Cui Q; Wei L; Huang JJ; Ashby CR; Chen ZS
Drug Resist Updat; 2020 Jan; 48():100663. PubMed ID: 31785545
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
